contrast reagent
Recently Published Documents


TOTAL DOCUMENTS

13
(FIVE YEARS 0)

H-INDEX

8
(FIVE YEARS 0)

2015 ◽  
Vol 51 (76) ◽  
pp. 14357-14360 ◽  
Author(s):  
Li Li ◽  
Jianbo Liu ◽  
Xiaohai Yang ◽  
Zhihong Peng ◽  
Wei Liu ◽  
...  

We present a novel large Stokes shifting NIR fluorescent nanomicelle through the encapsulation of a quantum dot/methylene blue FRET pair, which is employed as an excellent contrast reagent for NIR fluorescence bioimaging.


2012 ◽  
Vol 8 (4S_Part_19) ◽  
pp. P698-P699
Author(s):  
Valerie Anderson ◽  
James Obayashi ◽  
Phillip Berryhill ◽  
L.P. Riccelli ◽  
Joseph Quinn ◽  
...  

2010 ◽  
Vol 113 (2) ◽  
pp. 240-248 ◽  
Author(s):  
Dali Yin ◽  
R. Mark Richardson ◽  
Massimo S. Fiandaca ◽  
John Bringas ◽  
John Forsayeth ◽  
...  

Object The purpose of this study was to optimize stereotactic coordinates for delivery of therapeutic agents into the thalamus and brainstem, using convection-enhanced delivery (CED) to avoid leakage into surrounding anatomical structures while maximizing CED of therapeutics within the target volume. Methods The authors recently published targeting data for the nonhuman primate putamen in which they defined infusion parameters, referred to as “red,” “blue,” and “green” zones, that describe cannula placements resulting in poor, suboptimal, and optimal volumes of distribution, respectively. In the present study, the authors retrospectively analyzed 22 MR images with gadoteridol as a contrast reagent, which were obtained during CED infusions into the thalamus (14 cases) and brainstem (8 cases) of nonhuman primates. Results Excellent distribution of gadoteridol within the thalamus was obtained in 8 cases and these were used to define an optimal target locus (or green zone). Good distribution in the thalamus, with variable leakage into adjacent anatomical structures, was noted in 6 cases, defining a blue zone. Quantitative containment (99.7 ± 0.2%) of gadoteridol within the thalamus was obtained when the cannula was placed in the green zone, and less containment (85.4 ± 3.8%) was achieved with cannula placement in the blue zone. Similarly, a green zone was also defined in the brainstem, and quantitative containment of infused gadoteridol within the brainstem was 99.4 ± 0.6% when the cannula was placed in the green zone. These results were used to determine a set of 3D stereotactic coordinates that define an optimal site for infusions intended to cover the thalamus and brainstem of nonhuman primates. Conclusions The present study provides quantitative analysis of cannula placement and infusate distribution using real-time MR imaging and defines an optimal zone for infusion in the nonhuman primate thalamus and brainstem. Cannula placement recommendations developed from such translational nonhuman primate studies have significant implications for the design of anticipated clinical trials featuring CED therapy into the thalamus and brainstem for CNS diseases.


2008 ◽  
Vol 105 (46) ◽  
pp. 17937-17942 ◽  
Author(s):  
Xin Li ◽  
Wei Huang ◽  
Elizabeth A. Morris ◽  
Luminita A. Tudorica ◽  
Venkatraman E. Seshan ◽  
...  

The passage of a vascular-injected paramagnetic contrast reagent (CR) bolus through a region-of-interest affects tissue 1H2O relaxation and thus MR image intensity. For longitudinal relaxation [R1 ≡ (T1)−1], the CR must have transient molecular interactions with water. Because the CR and water molecules are never uniformly distributed in the histological-scale tissue compartments, the kinetics of equilibrium water compartmental interchange are competitive. In particular, the condition of the equilibrium trans cytolemmal water exchange NMR system sorties through different domains as the interstitial CR concentration, [CRo], waxes and wanes. Before CR, the system is in the fast-exchange-limit (FXL). Very soon after CRo arrival, it enters the fast-exchange-regime (FXR). Near maximal [CRo], the system could enter even the slow-exchange-regime (SXR). These conditions are defined herein, and a comprehensive description of how they affect quantitative pharmacokinetic analyses is presented. Data are analyzed from a population of 22 patients initially screened suspicious for breast cancer. After participating in our study, the subjects underwent biopsy/pathology procedures and only 7 (32%) were found to have malignancies. The transient departure from FXL to FXR (and apparently not SXR) is significant in only the malignant tumors, presumably because of angiogenic capillary leakiness. Thus, if accepted, this analysis would have prevented the 68% of the biopsies that proved benign.


2008 ◽  
Vol 295 (5) ◽  
pp. F1583-F1588 ◽  
Author(s):  
Christopher Peter Reinhardt ◽  
Michael J. Germain ◽  
Ernest V. Groman ◽  
Jeffrey G. Mulhern ◽  
Rajesh Kumar ◽  
...  

This is the first description of functional immunoassay technology (FIT), which as a diagnostic tool has broad application across the whole spectrum of physiological measurements. In this paper, FIT is used to measure the renal clearance of an ultra low-dose administration of a clinically available contrast reagent for the purpose of obtaining an accurate glomerular filtration rate (GFR) measurement. Biomarker-based GFR estimates offer convenience, but are not accurate and are often misleading. FIT overcomes previous analytic barriers associated with obtaining an accurate GFR measurement. We present the performance characteristics of this diagnostic test and demonstrate the method by directly comparing GFR values obtained by FIT to those obtained by an FDA approved nuclear test in 20 adults. Two subjects were healthy volunteers and the remaining 18 subjects had diagnosed chronic kidney disease, with 12 being kidney transplant recipients. Measured GFR values were calculated by the classic UV/P method and by the blood clearance method. GFR obtained by FIT and the nuclear test correlated closely over a wide range of GFR values (10.9–102.1 ml·min−1·1.73 m−2). The study demonstrates that FIT-GFR provides an accurate and reproducible measurement. This nonradioactive, immunoassay-based approach offers many advantages, chiefly that most laboratories already have the equipment and trained personnel necessary to run an ELISA, and therefore this important diagnostic measurement can more readily be obtained. The FIT-GFR test can be used throughout the pharmaceutical development pipeline: preclinical and clinical trials.


2008 ◽  
Vol 128 (3) ◽  
pp. 740-742 ◽  
Author(s):  
S.R. Rudrabhatla ◽  
W. Matthew Petroll ◽  
Christie L. Mahaffey ◽  
Mark E. Mummert
Keyword(s):  

2005 ◽  
Vol 53 (3) ◽  
pp. 724-729 ◽  
Author(s):  
Xin Li ◽  
Wei Huang ◽  
Thomas E. Yankeelov ◽  
Alina Tudorica ◽  
William D. Rooney ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document